Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
Sponsor: Ingenia Therapeutics INC
Summary
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is: Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)). Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use. Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.
Official title: A Randomized, Placebo-Controlled, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, and Pharmacokinetics of IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
94
Start Date
2025-10-30
Completion Date
2027-01
Last Updated
2025-12-05
Healthy Volunteers
Yes
Conditions
Interventions
IGT-303
IGT-303 administered via IV or SC
Placebo
Saline
Locations (1)
Nucleus Network
Herston, Brisbane, Australia